Merck Remains Committed to RNAi Despite Shuttering Its California Facility
August 04, 2011
Merck Remains Committed to RNAi Despite Shuttering Its California Facility
Merck confirmed that it is closing the San Francisco RNAi R&D facility it picked up through its acquisition of Sirna Therapeutics, but a spokesperson said that the company has not reduced its investment in the technology.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- RNAi Field Looks to Late-Stage Clinical Data, Approvals to Regain Pharma Interest
January 3, 2013 / Gene Silencing News - Quark, Pfizer Amend Deal for Ocular Disease Drug on Less-than-Ideal Phase II Data
March 24, 2011 / Gene Silencing News - Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi
January 6, 2011 / Gene Silencing News - In Changing RNAi Rx Guidance, Pfizer Becomes Latest Big Pharma to Shift Expectations
November 4, 2010 / Gene Silencing News - For Some RNAi Rx Shops, Industry Deals with Bigger Players are Par for the Course
August 20, 2009 / Gene Silencing News